← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications (1031)

• Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. (2018/11/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. (2018/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel treatments to tackle myelofibrosis. (2018/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver. (2018/11/01) ♡
• β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. (2018/11/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis. (2018/10/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Development of Serum Amyloid P as a Possible Therapeutic. (2018/10/16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. (2018/10/11) ♡
• Splenic mass in a case of CALR-mutated essential thrombocythemia. (2018/10/09) ♡
• Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance. (2018/10/02) ♡
• Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. (2018/10/01) ♡
• Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. (2018/10/01) ♡
• Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. What is pre-fibrotic myelofibrosis and how should it be managed in 2018? (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Reversible myelofibrosis due to severe Vitamin D deficiency rickets. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. (2018/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study(⁎). (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TAFRO Syndrome: A Case Report from Turkey and Review of the Literature. (2018/10/01) ♡
• Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs. (2018/10/01) ♡
• Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs. (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib. (2018/09/21) ♡
• Oxidative and nitrosative stress in myeloproliferative neoplasms: the impact on the AKT / mTOR signaling pathway. (2018/09/01) ♡
• Esophageal Variceal Hemorrhage Secondary to Post-Polycythemic Myelofibrosis. (2018/09/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Syndromic congenital myelofibrosis associated with a loss-of-function variant in RBSN. (2018/08/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature. (2018/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. An unusual presentation of primary myelofibrosis. (2018/07/01) ♡
• Bone Marrow Disease Profile in Geriatric Patients: An Institutional Experience. (2018/07/01) ♡
• The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis. (2018/06/01) ♡
• CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1-negative myeloproliferative neoplasms. (2018/05/01) ♡
• Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. (2018/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. (2018/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Plasma Cell Myeloma With Post-Therapy Anaplastic Morphology, Osteomyelosclerosis, and Strong Pan-Cytokeratin (AE1/AE3) Expression: A Potential Diagnostic Pitfall. (2018/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature. (2018/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin. (2018/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Systemic lupus erythematosus and myelofibrosis: A case report and revision of literature. (2018/04/10) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? (2018/04/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. (2018/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. (2018/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. (2018/04/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects. (2018/03/01) ♡
• The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. (2018/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. (2018/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. (2018/03/01) ♡
• Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. (2018/03/01) ♡
• Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. (2018/03/01) ♡
• Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. (2018/03/01) ♡
• Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. (2018/03/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. (2018/03/01) ♡
• Bone marrow findings in blast phase of polycythemia vera. (2018/03/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.